Skip to main content
SpringerLink
Log in

Rivastigmine for dementia associated with Parkinson’s disease

  • Clinical Trials Report
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cotzias GC, Van Woert MH, Schiffer LM: Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967, 276:374–379.

    Article  PubMed  CAS  Google Scholar 

  2. Kostrzewa RM, Kostrzewa JP, Brus R: Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson’s disease. Amino Acids 2002, 23:57–63.

    Article  PubMed  CAS  Google Scholar 

  3. Datla KP, Blunt SB, Dexter DT: Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. Mov Disord 2001, 16:424–434.

    Article  PubMed  CAS  Google Scholar 

  4. Rajput AH, Fenton M, Birdi S, Macaulay R: Is levodopa toxic to human substantia nigra? Mov Disord 1997, 12:634–638.

    Article  PubMed  CAS  Google Scholar 

  5. Fahn S, Elton RL; UPDRS Development Committee: Unified Parkinson’s disease rating scale. In Recent Developments in Parkinson’s Disease, vol 2. Edited by Fahn S, Marsden CD, Calne DB, et al. Florham Park, NJ: MacMillan Healthcare Information; 1987:153–163.

    Google Scholar 

  6. Ravina B, Eidelberg D, Ahlskog JE, et al.: The role of radiotracer imaging in Parkinson disease. Neurology 2005, 64:208–215.

    PubMed  CAS  Google Scholar 

  7. Benamer HT, Oertel WH, Patterson J, et al.: Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations. Mov Disord 2003, 18:977–984.

    Article  PubMed  Google Scholar 

  8. Lang AE, Obeso JA: Challenges in Parkinson’s disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004, 3:309–316.

    Article  PubMed  Google Scholar 

  9. Hely MA, Morris JG, Reid WG, Trafficante R: Sydney multicenter study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005, 20:190–199.

    Article  PubMed  Google Scholar 

  10. Parkinson J: An Essay on the Shaking Palsy. London: Sherwood, Neely, and Jones; 1817.

    Google Scholar 

  11. Brown RG, Marsden CD: How common is dementia in Parkinson’s disease? Lancet 1984, 2:1262–1265.

    Article  PubMed  CAS  Google Scholar 

  12. Cummings JL: The dementias of Parkinson’s disease: prevalence, characteristics, neurobiology, and comparison with dementia of the Alzheimer type. Eur Neurol 1988, 28(Suppl 1):15–23.

    PubMed  Google Scholar 

  13. Aarsland D, Andersen K, Larsen JP, et al.: Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003, 60:387–392.

    Article  PubMed  Google Scholar 

  14. Levy G, Tang MX, Louis ED, et al.: The association of incident dementia with mortality in PD. Neurology 2002, 59:1708–1713.

    PubMed  CAS  Google Scholar 

  15. Apaydin H, Ahlskog JE, Parisi JE, et al.: Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002, 59:102–112.

    Article  PubMed  Google Scholar 

  16. Emre M: Dementia in Parkinson’s disease: cause and treatment. Curr Opin Neurol 2004, 17:399–404.

    Article  PubMed  Google Scholar 

  17. Bohnen NI, Kaufer DI, Ivanco LS, et al.: Cortical cholinergic function is more severely affected in Parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003, 60:1745–1748.

    Article  PubMed  Google Scholar 

  18. McKeith I, Del Ser T, Spano PF, et al.: Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet 2000, 356:2031–2036.

    Article  PubMed  CAS  Google Scholar 

  19. Beatty WW, Ryder KA, Gontkovsky ST, et al.: Analyzing the subcortical dementia syndrome of Parkinson’s disease using the RBANS. Arch Clin Neuropsychol 2003, 18:509–520.

    Article  PubMed  Google Scholar 

  20. Bohnen NI, Kaufer DI, Hendricksn R, et al.: Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2005, 76:315–319.

    Article  PubMed  CAS  Google Scholar 

  21. Richard IH, Justus AW, Greig NH, et al.: Worsening of motor function and mood in a patient with Parkinson’s disease after pharmacologic challenge with oral rivastigmine. Clin Neuropharmacol 2002, 25:296–299.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. John Morgan MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kapil D. Sethi MD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Morgan, J., Sethi, K.D. Rivastigmine for dementia associated with Parkinson’s disease. Curr Neurol Neurosci Rep 5, 263–265 (2005). https://doi.org/10.1007/s11910-005-0070-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-005-0070-8

Keywords

Search

Navigation